These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 23567227

  • 1. [Pigmentary disorders induced by anticancer agents. Part II: targeted therapies].
    Sibaud V, Robert C.
    Ann Dermatol Venereol; 2013 Apr; 140(4):266-73. PubMed ID: 23567227
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice.
    Agostino NM, Chinchilli VM, Lynch CJ, Koszyk-Szewczyk A, Gingrich R, Sivik J, Drabick JJ.
    J Oncol Pharm Pract; 2011 Sep; 17(3):197-202. PubMed ID: 20685771
    [Abstract] [Full Text] [Related]

  • 4. Chemotherapeutic agents and the skin: An update.
    Heidary N, Naik H, Burgin S.
    J Am Acad Dermatol; 2008 Apr; 58(4):545-70. PubMed ID: 18342708
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Novel molecular targeted therapies for refractory thyroid cancer.
    Perez CA, Santos ES, Arango BA, Raez LE, Cohen EE.
    Head Neck; 2012 May; 34(5):736-45. PubMed ID: 21544895
    [Abstract] [Full Text] [Related]

  • 7. [Tyrosine kinase inhibiting the VEGF pathway and elderly people: Tolerance, pre-treatment assessment and side effects management].
    Bretagne M, Boudou-Rouquette P, Huillard O, Thomas-Schoemann A, Chahwakilian A, Orvoen G, Arrondeau J, Tlemsani C, Cessot A, Cabanes L, Blanchet B, Coriat R, Alexandre J, Goldwasser F.
    Bull Cancer; 2016 Mar; 103(3):259-72. PubMed ID: 26832420
    [Abstract] [Full Text] [Related]

  • 8. Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis.
    Montemurro M, Gelderblom H, Bitz U, Schütte J, Blay JY, Joensuu H, Trent J, Bauer S, Rutkowski P, Duffaud F, Pink D.
    Eur J Cancer; 2013 Mar; 49(5):1027-31. PubMed ID: 23140824
    [Abstract] [Full Text] [Related]

  • 9. Evidence for therapeutic drug monitoring of targeted anticancer therapies.
    Gao B, Yeap S, Clements A, Balakrishnar B, Wong M, Gurney H.
    J Clin Oncol; 2012 Nov 10; 30(32):4017-25. PubMed ID: 22927532
    [Abstract] [Full Text] [Related]

  • 10. From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage.
    Petrelli A, Giordano S.
    Curr Med Chem; 2008 Nov 10; 15(5):422-32. PubMed ID: 18288997
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Toxicities of antiangiogenic therapy in non-small-cell lung cancer.
    Herbst RS.
    Clin Lung Cancer; 2006 Dec 10; 8 Suppl 1():S23-30. PubMed ID: 17239287
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.